TITLE

PRONEURON STARTS 2ND PHASE 1 SPINAL CORD INJURY CLINICAL TRIAL

PUB. DATE
December 2001
SOURCE
Worldwide Biotech;Dec2001, Vol. 13 Issue 12, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Deals with the Phase 1 clinical trials for the autologous activated macrophage therapy for patients with complete spinal cord injury by Proneuron Biotechnologies at the Erasme Hospital in Brussels, Belgium. Design of the study; Significance of the trials; Basis of the therapy.
ACCESSION #
7120953

 

Related Articles

  • BIO, ASCO, and Clinical Trials. Henderson, Lisa // Applied Clinical Trials;May2009, Vol. 18 Issue 5, p12 

    The article discusses various reports published within the issue, including one on the benefits of early strategic development planning, another one on radiological measurement quality improvement, and a report on ways which could prove beneficial for biotech development in clinical trial stage.

  • Clinic Roundup.  // BioWorld Today;7/9/2010, Vol. 21 Issue 131, p2 

    This section offers news briefs on clinical trials in the biotechnology industry as of July 9, 2010, including the initial Phase I study for EP217609 in patients with thrombin generation from Endotis Pharma, the histology study of azficel-T by Fibrocell Science Inc. and the drug application of...

  • Clinical development?look before you leap. Fox, Anthony W. // Nature Biotechnology;Jun2001 Supplement 6, Vol. 19, pBE27 

    Focuses on measures to be taken by small biotechnology companies for the clinical trials of drug development. Measurement of tolerability and pharmokinetics of the drug in healthy human volunteers; Studies on a limited number of patients with the specified conditions; Evidence of the safety and...

  • Biotechnology and Clinical Trials. Siegel, Jay P. // Journal of Infectious Diseases;2/15/2002 Supplement, Vol. 185, pS52 

    Not surprisingly, clinical trials have been critically important to developments in the field of biotechnology. Perhaps less expectedly, the clinical trials of biotechnology products have been critically important to recent developments in the field of clinical trials design, conduct, and...

  • Clinic Roundup.  // BioWorld Today;9/2/2011, Vol. 22 Issue 171, p4 

    This section offers world news briefs relating to clinical trials in the biopharmaceutical industry as of September 2, 2011, including the enrollment of patients for the Phase IIb trial of KUR211 in diabetic foot ulcers by Kuros Biosurgery AG, the clearance received by ReNeuron Ltd. from an...

  • CancerVax, Kalypsys Land $83M in New Funding. Webb, Marion // San Diego Business Journal;4/8/2002, Vol. 23 Issue 14, p14 

    Reports on the fundings of biotechnology firms CancerVax Corp. and Kalypsys Inc. in San Diego, California. Use of the money for the development of biotechnology products; Evaluation of the cancer vaccine; Permission of the testing of the vaccine by the Food and Drug Administration.

  • Business News.  // Applied Clinical Trials;Sep2000, Vol. 9 Issue 9, p74 

    Reports developments related to the pharmaceutical and biotechnology industries in support for clinical trials in the United States as of September 2000. Agreements for joint medical ventures of companies; Mergers and product launching of medical companies; Expansion of clinical trial...

  • Calendar of Events.  // Applied Clinical Trials;Jul2006, Vol. 15 Issue 7, p56 

    The article presents a calendar of events on clinical trials and development for the month of July and August. A conference entitled "Seventh Annual Land O'Lakes Bioanalytical Conference" will be held on July 10-14 in Merrimac, Wisconsin. The "2006 World Congress on Industrial Biotechnology and...

  • Trial registry may be new policy for literature. Abelson, Mark B.; Plumer, Annie; Liner, Lisa // Ophthalmology Times;11/1/2005, Vol. 30 Issue 21, p1 

    The article that ophthalmologists who are clinical investigators are likely affected by trial registration policies if they intend to publish their research in top-tier journals in the United States. The allegations of selective publication and biased reporting of clinical trials have led to the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics